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ABSTRACT
Prostate cancer progression to castration refractory disease is associated with
anomalous transcriptional activity of the androgen receptor (AR) in an androgendepleted milieu. To identify novel gene products whose downregulation transactivates
AR in prostate cancer cells, we performed a screen of enzymatically-generated shRNA
lenti-libraries selecting for transduced LNCaP cells with elevated expression of a
fluorescent reporter gene under the control of an AR-responsive promoter. The shRNAs
present in selected populations were analyzed using high-throughput sequencing to
identify target genes. Highly enriched gene targets were then validated with siRNAs
against selected genes, testing first for increased expression of luciferase from an
AR-responsive promoter and then for altered expression of endogenous androgenregulated genes in LNCaP cells. We identified 20 human genes whose silencing
affected the expression of exogenous and endogenous androgen-responsive genes in
prostate cancer cells grown in androgen-depleted medium. Knockdown of four of these
genes upregulated the expression of endogenous AR targets and siRNAs targeting
two of these genes (IGSF8 and RTN1) enabled androgen-independent proliferation
of androgen-dependent cells. The effects of IGSF8 appear to be mediated through
its interaction with a tetraspanin protein, CD9, previously implicated in prostate
cancer progression. Remarkably, homozygous deletions of IGSF8 are found almost
exclusively in prostate cancers but not in other cancer types. Our study shows that
androgen independence can be achieved through the inhibition of specific genes and
reveals a novel set of genes that regulate AR signaling in prostate cancers.

metastatic disease but most treated patients will eventually
recur with castration refractory prostate cancer (CRPC)
that continues to grow and metastasize. Although ADT
maintains systemic castrate levels of androgen, studies
of CRPC tissues and experimental models of CRPC
support the notion that CRPC cells remain addicted to
AR-driven signaling. This is reinforced by the clinical

INTRODUCTION
Metastatic prostate cancer (PCa) patients are treated
with androgen deprivation therapies (ADT) to deplete
systemic androgen levels and inhibit androgen binding
to the androgen receptor (AR) protein in prostate cancer
(PCa) cells [1]. ADT extends survival of patients with
www.impactjournals.com/oncotarget
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success of new anti-androgens such as enzalutamide
that significantly increase survival of CRPC patients.
Mechanistic explanations for AR hyperactivity in CRPC
cells include: 1) increased AR expression (with or without
concomitant AR gene amplification); 2) AR mutations
that allow promiscuous activation by non-androgens; 3)
expression of constitutively active truncated AR
splice variants produced by alternate splicing [2]; 4)
intratumoral steroidogenesis that generates a local
tumor microenvironment enriched for testosterone/
dihydrotestosterone; 5) tumor cell overexpression of AR
co-activators that could further sensitize ARs in CRPC to
castrate level androgens or alternate steroids.
Here we considered the hypothesis that AR is
inherently capable of functioning under ADT but is
functionally suppressed by some other proteins. Reduced
expression of such proteins, a new class of PCa-specific
tumor suppressors, might facilitate progression to CRPC.
To identify genes that may act in this fashion, we developed
a shRNA lenti-library screening procedure to identify and
characterize genes, the knockdown of which increases the
androgen-independent (AI) activity of AR in PCa cells.
We combined a reporter-based selection procedure in
which shRNAs from transcriptome-scale, enzymaticallygenerated libraries activate an AR-responsive reporter in
androgen-dependent (AD) PCa cells (LNCaP) under the
conditions of androgen depletion. Our strategy involved
three sequential validation steps following the initial
screening. First, we tested siRNAs against gene targets that
were enriched following initial selection for the ability to
increase the expression of an AR-responsive reporter in
androgen-depleted medium. siRNAs that were validated at
this step were further tested for effects on the expression
of a panel of endogenous AR-regulated genes in androgendeprived cells. Finally, siRNAs that passed this validation
were tested for their ability to enable androgen-independent
growth of the cells. Using this protocol, we have identified
both known and novel effectors of androgen signaling in
androgen-deprived PCa cells. We further demonstrated that
some of these genes, when inhibited, permit AI growth of
AD cells, demonstrating for the first time that increased
AR signaling and AI growth can be achieved through the
inhibition of specific genes. Based on published studies, two
of the AR signaling modulators identified in our screening,
IGSF8 and CD9, appear to interact with each other in PCa
progression.

These cells were first sorted by FACS to enrich for
cells with minimal DsRed fluorescence in androgendepleted medium. Afterwards, they were again sorted
in the presence of R1881 to select for cells with high
DsRed fluorescence. The final population contained
cells with a maximum dynamic range of induction by
an AR ligand (Figure 1B). These reporter cells (PrbDsRed-LNCaP) expressed constitutively high levels of
DsRed when transduced with a lentivirus expressing
C-terminal truncated (constitutively active) AR, but not
after transduction with a control (insert-free) lentivirus
(Figure 1C). Two human shRNA libraries were used
for our screen. The first library was prepared from a
normalized mixture of cDNA from breast cancer cells (2.8
million total clones) and was previously described [4].
The second shRNA library was derived from a normalized
mixture of cDNAs from AD LNCaP cells and AI PC3
cells (1.5 million total clones, see Methods).
The selection protocol (Figure 1D) is described in
detail in Methods. Briefly, Prb-DsRed-LNCaP cells were
transduced with lentiviral shRNA libraries. DNA from
10% of transduced cells was extracted immediately after
transduction and used as a reference control; the remainder
were maintained for 10 days in androgen-depleted medium
to minimize basal reporter expression. Then, librarytransduced Prb-DsRed-LNCaP cells were FACS-sorted
for high DsRed expressers that constituted approximately
3% of the infected cells. Genomic DNA from the high
DsRed population was extracted, integrated shRNAs were
PCR-amplified and sequenced using 454 massive parallel
sequencing. BLAST analysis of the results yielded ~20,
000 sequences per dataset with homology to Unigene
clusters. We identified 2913 genes that were 4 fold or more
enriched in the high DsRed cell populations (summarized
in Supplementary Table S1). The sets of genes selected
using breast- and prostate-cell-derived libraries were
largely non-overlapping, mainly due to the relatively
low sequencing depth of the samples. Using this list of
enriched genes we performed a comprehensive automated
PubMed search to extract all publications relevant to
androgen signaling. This search identified 69 genes that
include both co-activators and inhibitors of AR-dependent
transcriptional activation (Supplementary Table S2).

Secondary siRNA screening and the effects of
screen-selected siRNAs on the expression of
endogenous androgen-regulated genes

RESULTS

The flow chart of our validation analysis is shown in
Figure 2A. Based on the level of enrichment we selected
200 genes (Supplementary Tables S3 and S4) from the
primary enriched target list for secondary validation with
individual siRNAs (4 different siRNAs per gene). We
excluded known androgen signaling regulators and focused
on genes that were not previously implicated in androgen
signaling. To limit cell line- or reporter-specific effects, we

shRNA library screening for activation of an
AR-responsive promoter
LNCaP cells were stably transduced with a
recombinant lentiviral vector expressing red fluorescent
protein (DsRed) under the control of a modified rat
probasin gene promoter (pARR2PB) [3] (Figure 1A).
www.impactjournals.com/oncotarget
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Figure 1: High throughput screening for shRNAs stimulating AR activity in low androgen environment. A. AR-driven

reporter construct containing Red fluorescent protein (DsRed II) under control of modified rat probasin promoter. B. FACS analysis of
Prb-DsRed-LNCaP reporter cells. Cells were cultured in a hormone-free medium for 8 days (left). Cells were cultured in a hormone-free
medium for 6 days followed by 48 h treatment with 100pm R881 (right). C. DsRed fluorescence is increased in Prb-DsRed-LNCaP reporter
cells infected with AR-expressing (right) or a control lentiviral vector (left) and cultured for 8 days in hormone-free conditions. DIC (top)
and fluorescence (bottom) microscopy, 20x magnification. D. Scheme of the selection and analysis of the shRNAs stimulating rat probasin
promoter under hormone-free conditions.

tested siRNAs using a different reporter cell line, LNCaP
cells with integrated probasin-luciferase reporter (PrbLuc-LNCaP, Figure 2B, 2C). Each siRNA was transfected
individually into reporter cells that were then maintained
in androgen-depleted medium and assayed for luciferase
activity. The total amount of DNA in each sample was
used to normalize the reporter activity. siRNAs were
considered positive in this screen if at least two different
siRNAs increased normalized luciferase expression by at
least 1.5-fold over control siRNA-transfected cells.
Among the genes identified by our screen, nine
encode different components of the 19S proteasome
www.impactjournals.com/oncotarget

(highlighted in Figure 3A). It was previously shown that
siRNA-mediated disruption of the 19S subunit inhibited
AR signaling [5, 6]. Since this was the most enriched
class of genes in our selection, we analyzed the effects of
the depletion of all the different 20S and 19S proteasome
subunits on the activity of the probasin promoter under
androgen-free conditions. Whereas all siRNAs targeting
19S subunit genes dramatically increased luciferase
reporter expression compared to non-targeting control
siRNA, siRNAs targeting 20S subunit genes failed to
achieve this effect (Figure 3C). Importantly, depletion of
19S proteins resulted in a 14-fold elevation of luciferase
13090
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Figure 2: Validation of shRNA library selection procedure. A. Scheme of library screening and validation procedure. B. The

AR-driven reporter construct containing Firefly Luciferase (FFLuc) under control of modified rat probasin promoter (validation, step 1)
C. Androgen dose-dependent activity of the integrated luciferase reporter in Prb-Luc-LNCaP cells D. Localization of Androgen Responsive
Elements (AREs) in the endogenous genes selected for QPCR based validation. Grey boxes represent canonical AREs, black box represents
a non-canonical ARE.

mRNA, confirming the effect on the probasin promoter
and arguing against potential stabilization of luciferase
protein upon proteasome depletion (Figure 3B). Hence,
our selection identified not only individual genes but also
specific functionally related classes of genes that regulate
the AR-dependent promoter function.
40 different siRNA sets with two or more siRNAs
that upregulated luciferase expression in reporter cells
www.impactjournals.com/oncotarget

were selected for the second validation step. Here,
we determined the effects of the most active siRNAs
for each gene on the expression of 4 endogenous ARresponsive genes with differing regulatory architectures
(Figure 2D). We transfected the 40 most active siRNAs
as well as a control siRNA into parental (non-reporter)
LNCaP cells and, after 6 days androgen-depletion used
qPCR to evaluate the expression levels of endogenous
13091
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Figure 3: Effects of knockdown of proteasome complex subunits. A. Effects of siRNAs against the indicated proteasome

components (4 siRNA per gene, sets A–D) on Prb-promoter activity measured by luciferase expression in Prb-Luc-LNCaP cells. Genes
enriched in shRNA library selection are highlighted. Cells were transfected with siRNAs (5 nM) in duplicates, cultured in hormone-free
medium for 6 days, followed by measurement of luciferase activity. B–C. Reporter Prb-Luc-LNCaP cells were transfected with siRNA
against 19S proteosomal component PSMC4 (5 nM), cultured in hormone-free medium for 6 days, followed by QPCR analysis of expression
of firefly luciferase B. or endogenous androgen responsive genes C. Results represent mean of 3 independent experiments +/– SD.

AR targets such as KLK2, KLK3 (PSA), TMPRSS2
and FKBP5 (Figure 2A). siRNAs targeting 20 genes
significantly affected the expression of endogenous
androgen-regulated genes (Figure 4 and Supplementary
Table S5) without any significant effect on the expression
www.impactjournals.com/oncotarget

of AR mRNA (data not shown). Although the magnitude
of the effects varied, depending on the specific
endogenous gene and siRNA, we grouped the effective
siRNAs into two classes: 1) those which mainly induced
expression of endogenous androgen-regulated genes
13092
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(4 siRNAs) and; 2) those which suppressed expression
of endogenous genes (16 genes) (Figure 4A). Although
siRNAs of both classes induced luciferase expression
from the probasin promoter, all four genes in the first
class induced the reporter by >5-fold, whereas only one
of 16 genes in the second class had such a strong effect
on the reporter (Figure 4A). To further confirm the target
specificity of the selected siRNAs, we determined the
effects of three independent siRNAs targeting PUF60,
an RNA binding protein and negative regulator of
c-MYC expression, on endogenous AR-regulated
genes. All three siRNAs that reduced PUF60 expression
(Supplementary Figure S2A) also significantly reduced
the expression of KLK2, KLK3 and to a lesser degree,
FKBP5, whereas only one siRNA significantly reduced
the expression of TMPRSS2 in both androgen-free
conditions and in the presence of 100 pM R1881
(Supplementary Figure S2B, S2C).
Since the activity of co-regulators of steroid
hormone receptors are often context-dependent [7–9],
it is not surprising that the activity of genes that inhibit
AR-dependent transactivation of the probasin promoter
had different effects on different endogenous genes. Most
of the active siRNAs affected mRNA levels of KLK2
and KLK3 (PSA) genes, promoters of which, similar
to probasin, contain multiple canonical AREs [5, 11].
In contrast, FKBP5 and TMRSS2 genes, which contain
either intronic or non-canonical AREs (Figure 2D) were
considerably less affected (Figure 4A) [10, 11]. Therefore,
the selection protocol that relies on ARE-driven reporter
expression appears to target preferentially endogenous
genes with canonical AREs upstream of the transcription
initiation site.

determined the mRNA levels of AR target genes after
6 days in androgen-depleted medium. Two different
IGSF8-targeting siRNAs yielded greater than 90% IGSF8
mRNA depletion (Figure 5A). Both of these siRNAs
also significantly upregulated endogenous mRNA levels
of KLK2, KLK3 and TMPRSS2 in androgen-deprived
LNCaP cells, while neither had a significant effect on
FKBP5 expression (Figure 5B). To test whether AR is
involved in IGSF8-dependent activation of endogenous
genes we depleted IGSF8 and AR simultaneously.
Co-transfection of IGSF8–2 siRNA and AR siRNA
suppressed the ability of the IGSF8 siRNA to induce
KLK2 and KLK3 expression (Figure 5C) indicating that
the effect of IGSF8 was exerted through AR. Several of
the siRNAs that affected the expression of AR targets
in our screen targeted the tetraspanin protein CD9
that physically interacts with IGSF8 [12]. Curiously,
however, CD9 belonged to the second class of AR
regulators, as its knockdown decreased the expression
of several AR target genes, including KLK2, KLK3
and TMPRSS2 (Figure 4A). As shown in Figure. 5D,
siRNA-mediated depletion of CD9 downregulated the
expression of KLK2 and KLK3 when used either alone
or in combination with IGSF8 shRNA (Figure 5D). To
further elucidate the effects of IGSF8 depletion on AR,
we analyzed the expression of the AR protein in IGSF8
knockdown cells. IGSF8 knockdown strongly induced
PSA expression (Figure 6A), it affected neither the
expression (Figure 6A, 6B) nor the nuclear localization
of the AR protein (Figure 6B). Finally, the androgen
receptor antagonist enzalutamide drastically inhibited the
induction of both KLK2 and PSA by IGS8 knockdown,
with only minor effects on the expression of AR and
IGSF8 (Figure 6C), indicating that the effect of IGSF8
knockdown was mediated by AR.
Our data show that a subset of known androgenresponsive genes is upregulated by IGSF8 knockdown.
To compare the transcriptomic effects of IGSF8 and AR,
we analyzed gene expression profiles by microarrays
using (i) LNCaP cells with IGSF8 knockdown
in androgen-depleted medium; (ii) LNCaP cells
stimulated with 10pM of R1881 for 24 hours; (iii) cells
transfected with control siRNA in androgen-depleted
medium; and (iv) untreated LNCaP cells in androgendepleted medium. 2357 (7.1%) and 1625 (5%) genes
were significantly (>1.4 fold, P < 0.05) affected by
R1881 treatment or IGSF8 knockdown, respectively.
Strikingly, 34% of R1881-regulated genes and 49% of
IGSF8 siRNA-responsive genes were regulated by both
R1881 and IGSF8 siRNA. 55 genes were upregulated
and 157 downregulated by both androgen and IGSF8
knockdown (Figure 7A, Supplementary Table S6). The
majority of genes that were induced both by androgen
and by IGSF8 shRNA are well-known AR targets,
including KLK3(PSA), KLK2, KLK4, PPAP2A,
C19orf48, cdc2, and NFKB2 [13–16]. Many AR targets

Effects of selected siRNAs on PCa cell growth in
androgen deprived medium
We assessed the effects of all four screen-selected
siRNAs of the first class (targeting RTN1, IGSF8,
C14orf147 (SPTSSA) and DYDC2, Figure 4A) on the
growth of LNCaP cells in androgen-deprived medium.
Each siRNA was transfected into LNCaP cells that were
subsequently maintained in androgen-depleted medium.
Two siRNAs, against ISFG8 and RTN1 enabled AD
LNCaP cells to grow in androgen-deprived medium while
two other siRNAs (C14orf147, DYDC2) and a control
non-targeting siRNA had no effect (Figure 4C).

Effects of IGSF8 knockdown on the expression
of androgen receptor-regulated genes
Because depletion of IGSF8 conferred the strongest
AI growth on LNCaP cells, we analyzed in detail the
effect of IGSF8 knockdown on the expression of AR
target genes. We designed an independent set of siRNAs
against IGSF8, transfected them into LNCaP cells, and
www.impactjournals.com/oncotarget
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Figure 4: New regulators of androgen-responsive genes identified in the functional screening. A. Two groups of siRNA
regulators were discovered: androgen independent activators and inhibitors of androgen responsive genes. The expression of 4 known
androgen-responsive genes (KLF3 (PSA), KLK2, FKBP5 and TMPRSS2) was measured following transfection of selected siRNAs (at
5 nm) into LNCaP cells in triplicates (see Figure 2). Cells were cultured in androgen-free conditions for 6 days. mRNA was purified
and subjected to QPCR analysis. Table represents the levels of gene expression as percentages compared to control (the description of
genes is presented in Supplementary Table S5). First column represents the effect of selected siRNAs on expression of luciferase in PrbLuc-LNCaP cells (in triplicate) B. Three GO categories enriched in the validated group of genes. C. Screen-selected siRNAs enable
proliferation of LNCaP cells under hormone-free conditions. LNCaP cells were transfected with siRNAs as shown and cultured under
androgen-free conditions. The number of viable cells was determined using spectrophotometric quantification of cell proliferation by WST1 assay. The plot represents the mean of six independent transfections +/– SD.

affected by IGSF8 knockdown are known positive
and negative regulators of cancer cell proliferation
and survival. For example, cdc2 [17–19] and NFKB2
[20–22] enhance androgen-independent growth, and
HMGCS2 [23] , PIK3AP1 [24], ABCC4 [25], SLC1A5
[26], CYP3A5 [27] genes are associated with PCa
progression. Furthermore, many genes downregulated
by IGSF8 knockdown are markers of neuroendocrine
differentiation (OPRK1 [28, 29], PNMA2 [30], IGFBP3
[31]), cell-adhesion proteins (PCDHB10, PCDHB15,
PCDHB8, PCDHB16, PCDHB18, PCDHB12,
www.impactjournals.com/oncotarget

PCDHB4), targets of AR-regulated transcriptional
repressor REST [32, 33], and genes associated with
suppression of prostate and other cancers (SERPINI1
[34], ODZ2 [35], SI [36], TLR5 [37, 38], RNF180
[39], FBXL2 [40–42], TRIM45 [43]). A large cohort
of genes was differentially regulated by IGSF8
knockdown and androgen (Figure 7B, Supplementary
Table S6). These include 292 genes upregulated by
IGSF8 knockdown, while downregulated by R881
including pro-oncogenic genes (VAV3 [44–47], REG4
[48, 49], SYP2 [50], ZNF706 [51, 52], SHC4 [53])
13094
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Figure 5: siRNA-mediated depletion of IGSF8 activates the expression of androgen responsive genes. A. Two different

siRNAs efficiently inhibit expression of IGSF8 gene (QPCR analysis). B. LNCaP cells were transfected with IGSF8-targeting or control
siRNAs (5 nM) and cultured in hormone-free conditions for 6 days. Expression of androgen responsive genes was analyzed by QPCR.
The results represents mean of 3 independent experiments +/– SD. C. Effect of the IGSF8 knockdown is AR-dependent. LNCaP cells were
transfected with control, IGSF8 or AR siRNAs and cultured in hormone-free conditions for 6 days. Expression of androgen responsive
genes was analyzed by QPCR. D. Effects of the IGSF8 knockdown depend on the expression of CD9. LNCaP cells were transfected with
control, IGSF8 or CD9 siRNAs and cultured in hormone-free conditions for 6 days. Expression of androgen responsive genes was analyzed
by QPCR. All QPCR results represent mean of 3 independent experiments +/– SD.

and biomarkers of PCa progression (PLA2G2A [54],
CLU [55]). 298 genes were downregulated by IGSF8
knockdown while upregulated by R1881 including
a cluster of UDP glucuronosyltransferase 2 family
genes (UGT2B7, UGT2B17, UGT2B15, UGT2B11,
UGT2B10, UGT2B4, UGT2B28, UGT2B7). UGT2B
enzymes are mainly responsible for DHT degradation in
prostate tissues [56–58]. The main triggers of androgen
degradation, UGT2B17 and UGT2B15, were shown
to be upregulated by activated AR [59], while they
were drastically (>20-fold) downregulated by IGSF8
www.impactjournals.com/oncotarget

knockdown. The expression levels of UGT2B17 and
UGT2B15 were verified by QPCR in LNCaP with
IGSF8 knockdown (with 2 independent siRNAs)
(Supplementary Figure S3).
Potential alterations of the IGSF8 gene
across various human cancers were analyzed using
cBioPortal [60] (Figure 7C). IGSF8 is amplified in
a majority of cancer types, except prostate cancers,
where homozygous deletions were detected in 2% of
analyzed samples (in 5 out of 244 samples of prostate
adenocarcinomas) (Figure 7C).
13095
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Figure 6: IGSF8 knockdown effects is dependent of AR but does not change AR expression. A. LNCaP cells were transfected
with control or IGSF8-targeting siRNAs (5 nM) and cultured in hormone-free conditions for 6 days. Expression of AR and PSA was
analyzed by immunoblotting. Quantification of AR signal intensity normalized to GAPDH signal is shown on the right, relative to AR level
of untransfected LNCaP cells (mean of 3 independent experiments +/– SD). B. LNCaP were transfected as above, followed by fixation and
immunostaining with DAPI and anti-AR antibodies. Images were taken and nuclear staining was quantified. The results represent average
quantification of the AR to DAPI ratio of fluorescence intensity (30 nuclei per siRNA) +/– SD. C. LNCaP cells were transfected as in A
and cultured in hormone-free conditions for 6 days in the presence of 10 μM of Enzalutamide or DMSO. Gene expression was analyzed by
QPCR. The results represent mean of 3 independent experiments +/– SD.

DISCUSSION

(i) high-complexity enzymatically generated shRNA
libraries that target not only known but also uncharacterized
transcripts (both coding and non-coding); (ii) FACS
selection of library-infected cells with activated expression
of a fluorescent reporter; and (iii) analysis of shRNA
enrichment through massive parallel sequencing followed
by target identification and validation. The elements of
the screening procedure, including target identification
through massive parallel sequencing of enzymaticallygenerated shRNA libraries, were described previously [4].
The combination of the key elements we developed allows
for a robust and cost effective screening that can be used

CRPC is thought to be the consequence of
dysregulated (hyperactive) androgen signaling in PCa cells
that develops subsequent to chronic ADT. In this study, we
developed a robust procedure for the identification of new
co-regulators of AR that may participate in progression to
CRPC. High throughput screens to identify co-regulators
of hormone-dependent activation of AR transcriptional
activity have been reported [61], but screens for the
regulators of AR in hormone-free conditions have, to our
knowledge, not been done before. Our procedure employed
www.impactjournals.com/oncotarget
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Figure 7: Comparison of gene expression affected by IGSF8 knockdown or androgen stimulation. Affymetrix array

analysis of gene expression profiles of cells with siRNA knockdown of IGSF8 or treated with R1881. Diagrams represent changes in gene
expression > 1.4-fold (P < 0.05). A. Genes co-regulated by ISF8 knockdown and R1881 treatment. B. Genes differentially regulated by
IGSF8 siRNA and R1881. C. Genetic alterations of IGSF8 in human cancers analyzed through cBioPortal tool (TCGA provisional data set).

for fast identification of co-regulators and the dissection of
pathways regulated by any other transcription factors.
Using the multistep screening procedure (Figure 2A),
we identified 20 genes, knockdown of which affected
www.impactjournals.com/oncotarget

the expression of both the probasin-regulated reporter
and endogenous androgen-regulated genes. Knockdown
of four of these genes results in an upregulation of
endogenous AR target genes, while inhibition of the
13097
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other 16 downregulated endogenous gene expression.
The opposite effects of the latter siRNAs on the modified
probasin promoter and endogenous genes parallel the
reported effects on promoter-dependent activity of
previously described co-regulators of AR and other
steroid-hormone receptors [9, 62, 63]. In particular, the
knockdown of components of the proteosome 19S subunit
strongly activates expression from probasin promoter and
strongly inhibits the expression of KLK2 and KLK3 in
agreement with previous reports [64, 65]. The pleotropic
effect of proteosomal inhibition on gene expression
causing either upregulation or downregulation of different
groups of genes was shown for other steroid hormone
receptors (glucocorticoid and estrogen receptors) [66–68].
Our target enrichment list included five genes
associated with chromatin remodeling to a transcriptionally
active state or with the transcription process (HAT1,
SUPT16H and SMARCE1, POLR2H, ZNF146), a cluster
of five RNA/ribonucleoprotein binding proteins (PUF60,
RPL36AL, ASCC3L1, MRPS17 and RPL5), three genes
encoding transmembrane proteins (RTN1, IGSF8, CD9)
and two genes associated with GTPase signaling activities
(AIG1, RABL5) (Figure 4B). Analysis of the association
network of identified genes (Supplementary Figure S1)
suggests potential mechanisms of activation of the expression
of androgen-responsive genes by DYDC2, RTN1 and
C14orf147.
RTN1 (reticulon 1 or neuroendocrine specific
protein), knockdown of which enables androgenindependent proliferation of LNCaP cells, is a
neuroendocrine cell specific protein, localized in
endoplasmic reticulum [69]. RTN1 was shown to
interact with HDAC8 [70], a multifunctional histone
deacetylase with dual nuclear and cytoplasmic
localization [71]. Knockdown of RTN1 could increase
the nuclear pool of HDAC8. Nuclear HDAC8
was shown to regulate activities of transcription
factors, including nuclear hormone receptors [72].
C14orf147 (serine palmitoyltransferase, Small
Subunit A, SPTSSA) is a regulatory subunit of serine
palmitoyltransferase (SPT) [73].SPT (localized in
endoplasmic reticulum) is the first enzyme of the
ER-localized ceramide biosynthesis pathway [74].
Ceramide was shown to inhibit AR activity and
androgen independent growth of PCa cells through
activation of protein phosphatase 2A (PP2A) [75].
Depletion of SPTSSA inhibits activity of SPT [76] and
decreases ceramide accumulation [77], which in turn
may cause partial inhibition of PP2A activity followed
by AR activation. There is very little information about
the function and activity of DPY30 Domain-Containing
Protein 2 (DYDC2). The interaction network
(Supplementary Figure S1) suggests that DYDC2 may
influence AR activity through interaction with NME5
(NME/NM23 Family Member 5) or through HAT1
(histone acetyl transferase) activity.
www.impactjournals.com/oncotarget

We performed a more extensive characterization
of IGSF8, the knockdown of which not only activates
endogenous AR targets but also enables AI growth of
LNCaP cells. The effect of IGSF8 knockdown was
inhibited by the androgen antagonist Enzalutamide,
indicating that it was mediated by AR. A close association
of IGSF8 with androgen signaling is also indicated by
a very high overlap between the sets of the genes that
are affected either by the addition of androgen or by
IGSF8 knockdown. IGSF8, an immunoglobulin family
member, was originally identified as a binding partner
of tetraspanin family proteins, CD9 and CD81, which
modulates their activities [78]. There is evidence that
IGSF8 may affect membrane interaction and localization
of tetraspanins [12, 79]. shRNAs targeting both CD9
and CD81 were enriched in our shRNA library selection.
Knockdown of CD9 with individual siRNAs inhibited
the expression of all tested AR-responsive genes (Figure
3A) but did not affect AI growth of LNCaP cells (data
not shown). Based on our results showing that knockdown
of CD9 inhibits the expression of AR-responsive genes,
we hypothesize that tetraspanins are involved in the
activation of ligand-independent activity of AR. There
are several pathways downstream of CD9 which, when
activated, could be involved in the regulation of AR
activity. CD9 activates MAP kinase pathways [80–82],
which in turn may lead to AR activation by MAPK
phosphorylation [83–85]. Additionally, AR and CD9
share a common binding partner, ADAM10 that has a
dual function as a metalloproteinase and a co-activator
of AR dependent transactivation [86, 87]. Modulation
of CD9 activity through IGSF8 knockdown could lead
to CD9 relocalization from membrane to the nucleus
and interaction with AR. Finally, other as yet unknown
pathways could be involved in CD9 dependent regulation
of AR activity due to the pleotropic effects of tetraspanins.
The latter hypothesis is supported by recent results [88]
showing nuclear localization of both CD9 and IGSF8 in
breast carcinoma cells. That study showed that nuclear
CD9 may be involved in regulation of mitosis, therefore
IGSF8 inhibition may activate CD9 effects on both cell
division and AR transcriptional regulation.
Expression level and outcome of CD9 activity
in human tumors depends on the tumor origin. CD9
expression is correlated with poor prognosis of gastric
cancer whereas the expression in melanomas, myelomas,
and head and neck squamous carcinomas is associated with
early stages of cancer progression and positive treatment
outcome [89, 90]. CD9 expression declined significantly
as benign prostate epithelial cells progress from early
malignancy to metastasis [91]. Recent findings suggest that
the downregulation of CD9 expression is concomitant with
the production of a truncated CD9 isoform through cancer
specific gene fusion [92]. Moreover, the novel CD9 fusion
genes in prostate cancer lack the IGSF8 binding epitope
[93]. Thus it is tempting to speculate that the function of
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IGSF8 is linked to the suppression of androgen signaling
in PCa cells expressing unaltered CD9. This is supported
by evidence of IGSF8 deletions in prostate tumors. Both
CD9 translocations and IGSF8 deletions are observed in
2–3% of prostate tumors. Therefore, activation of CD9
either by IGSF8 deletion or CD9 translocation could be
involved in the development of CRPC.
Tumor suppressor activities of IGSF8 have been
previously addressed in PCa, although with respect
to cell motility rather than AR signaling [94], and in
glioblastomas [95]. The involvement of CD9 and IGSF8
in glioma progression is consistent with our findings in
PCa: elevation of CD9 expression and downregulation of
IGSF8 correlated with progression of malignant glioma
[95, 96], Although IGSF8 is frequently downregulated in
gliomas, cBioPortal does not show any rearrangements
of IGSF8 in gliomas. It seems likely that, in spite of the
rarity of IGSF8 deletion in prostate cancers, the level of
IGSF8 protein may also be reduced in prostate tumors by
epigenetic mechanisms.
Known mechanisms of transition from AD to AI
growth in PCa include AR overexpression, AR mutations
and expression of AR splice variants. There are, however,
many examples of PCa cell lines or tumors with elevated
AR signaling but without obvious changes in AR itself.
Our results provide, to the best of our knowledge, the
first examples of the transactivation of AR signaling and
the acquisition of AI growth through the inhibition of
specific genes. Other trans-repressors and trans-activators
of AR signaling that can confer androgen independence
can be identified through the approach developed in the
present study. Analysis of such regulatory genes in clinical
CRPC should greatly enrich our understanding of the
mechanisms of androgen independence in prostate cancer
and suggest new approaches to overcoming this major
clinical problem.

cells cultured on polyethyleneimine-coated plates [98].
Lentivirus-containing supernatants were harvested thrice,
at 24, 48 and 72 hours after transfection.

Cell culture
Human PCa cell lines LNCaP and PC3 from the
ATCC (Manassas, VA) were maintained in RPMI-1640
medium with 10% fetal bovine serum (FBS) or switched
to phenol red-free RPMI-1640 with 10% charcoalstripped FBS (CS-FBS) for androgen-depleted conditions
as previously described [99]. The 293FT cells from Life
Technologies (Grand Island, NY) were maintained in
DMEM with 10% FBS. R1881 (methyltrienolone), was
obtained from PerkinElmer Life Sciences (Boston, MA).
Reporter cell lines Prb-DsRed-LNCaP and Prb-LucLNCaP were prepared as described in Supplementary
Methods.

Construction of normalized shRNA libraries
The shRNA library originating from MCF7 breast
carcinoma cDNA was previously reported [4]. Preparation
of the prostate-specific shRNA library was similar to
previously described procedure [4]. (See construction
details in Supplementary Methods.)

Library transduction, selection for activation
of probasin promoter and analysis of
selection results
shRNA libraries were transduced into Prb-DsRedLNCaP reporter cells. The infection rate (as determined
by qPCR analysis of integrated provirus) was 95%. The
total of 108 cells were plated at a density of 107 cells per
plate, and cultured in androgen-free conditions (phenol
red-free RPMI-1640 with 10% CS-FBS) for 10 days.
25% of the cells were collected for DNA purification, the
rest were subjected to FACS sorting to collect the total
of 6x105 DsRed positive cells. DNA was purified from
unsorted and DsRed positive cells. The shRNA inserts
were amplified by two rounds of PCR from genomic
DNA preparations of the unsorted and DsRed positive
cells and sequenced using 454 Sequencer (Roche).
shRNA sequence attribution was done as previously
described [4, 97].

MATERIALS AND METHODS
Plasmids and vectors
Vectors containing rat probasin promoter (ARR(2)
PB) [3] were obtained from Dr. Robert J. Matusik
(Vanderbilt University, Nashville, TN). The promoter
was inserted into DsRed and luciferase reporter lentiviral
vectors to create pLR-PRBp-DsRed-DR and pLLRMPRbp-Luc constructs correspondently (see construction
details in Supplementary Methods). pLLCEmGFP
lentiviral vector was previously described [97].

Screening of siRNAs and luciferase activity assay
Four siRNAs per gene, obtained from Qiagen
Human Whole Genome siRNA set 1.0, were transfected
into Prb-Luc-LNCaP cells in PEI coated 96-well plates
(10, 000 cells per well) [98], in triplicate, at 5 nM of
siRNA per well using Silentfect transfection reagent
(BioRad) and reverse transfection procedure per Qiagen
(Highperfect) instructions. A cytotoxic mixture of siRNAs

Lentiviral infection
Lentiviral transduction was done as described [4]
using pCMV-∆8.9 and pVSV-G packaging constructs.
Vector plasmid, pCMV- ∆8.9, and pVSV-G DNA were
mixed at a 5:4:1 ratio and cotransfected into 293FT
www.impactjournals.com/oncotarget
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Immunofluorescence

derived from several essential genes (Qiagen, All-star cell
death Hs siRNA, #1027298) and anti-luciferase siRNA
(Qiagen, Luciferase GL3 siRNA, # 1022073), were used
as positive controls, and siRNA targeting no known genes
(Qiagen, Negative Control siRNA #1022076) was used as
a negative control. Cells were cultured in phenol red-free
RPMI-1640 with 10% CS-FBS 6 days post transfection,
washed with PBS and lysed for 60 min with 100 μL of cell
lysis buffer (0.22% NaCl, 0.15% Saponin, 1 mM EDTA)
containing 0.5 μg/mL Hoechst 33342 (Polysciences Inc,
Warrington, PA, #23491-52-3) that stains cellular DNA.
Relative cell numbers were determined by Hoechst 33342
fluorescence. Luciferase activity was determined with
prepared luciferase reporter reagents [100]. The ratio of
firefly luciferase activity/Hoechst 33342 fluorescence was
scored as normalized luciferase activity.

Cells cultured on glass coverslips (Bellco Glass,
Vineland, NJ) were fixed with 4% paraformaldehyde
in PBS for 20 minutes at room temperature and
permeabilized with 0.5% Triton X-100 in PBS for 3
minutes. The coverslips were incubated with rabbit antiAR H-280 antibodies and DAPI (Life Technologies, CA).
The secondary antibody was labeled with Alexa Fluor
488 (Life Technologies, CA). Fluorescence images were
acquired with a 40x/0.60 n.a. LUCPlan FLN objective
on an Olympus IX81 microscope. Hamamatsu C10600
camera gain and exposure time settings were controlled
with Metamorph Basic. Nuclear fluorescence intensities
were measured with ImageJ (NIH).
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LNCaP cells were transfected with siRNAs in PEI
coated 96-well plates (2000 cells per well) as described
above. Cell proliferation was analyzed by WST-1 assay
with WST-1 cell proliferation reagent (Roche Lifescience,
Indianapolis, IN).

QPCR and microarray analysis of
gene expression
LNCaP cells were transfected with siRNAs against
indicated genes (Supplementary Table S7) as described
above. Total cellular RNA was purified with either RNeasy
kit (Qiagen) or TRIzol (Life Technologies, Grand Island,
NY). Microarray analysis using Affymetrix Exon 1.0ST
human oligonucleotide arrays was conducted by Ordway
Research Institute’s Microarray Facility. Microarray data
were analyzed using GeneSpring GX (Agilent, Santa Clara
CA). For quantitative PCR (qPCR) analysis, cDNA was
prepared using Maxima First Strand cDNA Synthesis
(Thermo Scientific, Waltham, MA). Gene expression
was measured by QPCR, with gene specific primers and
GAPDH or RPL13A as normalization standards (primer
sequences are presented in Supplementary Table S8) using
RT2 SYBR Green qPCR Master Mixes (Qiagen).
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